TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28614364

Group type: EXPERIMENTAL
Intervention: Pre-peritoneal bolus of 30ml bupivacaine 0.25%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Epidural bolus of 10ml bupivacaine 0.25%
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Continuous wound infiltration (CWI)
Number of subjects: 20
Study: 26525144

Group type: EXPERIMENTAL
Intervention: Multisystemic therapy for problem sexual behaviour (MST-PSB)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Management as usual
Number of subjects: 80
Study: 23883510

Group type: EXPERIMENTAL
Intervention: Virtual haptic simulator for fixation of an ulna
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sawbones
Number of subjects: 22
Study: 21721591

Group type: EXPERIMENTAL
Intervention: Oxybutynin chloride topical gel (OTG) 1 g containing oxybutynin chloride 10%, applied once daily to the abdomen, upper arm/shoulder, or thigh.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Post-application showering (1-6 hours after dosing) and sunscreen application (30 minutes before or after OTG application).
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact (transference study) between treated and untreated participants.
Number of subjects: 12
Study: 20053323

Group type: EXPERIMENTAL
Intervention: Alefacept treatment
Number of subjects: 426
Study: 16954128

Group type: EXPERIMENTAL
Intervention: High-velocity, low-amplitude manipulation (HVLA)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (simulated performance-enhancement stickers)
Number of subjects: 19
Study: 15138107

Group type: EXPERIMENTAL
Intervention: lamivudine 100 mg daily
Number of subjects: 429

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 429
Study: 10977011

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Multiple daily injections (MDI)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Both CSII and MDI
Number of subjects: 41
Study: 9580803

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous apomorphine infusion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Patch testing to apomorphine and its preservative
Number of subjects: 10

Group type: COMPARATOR
Intervention: Serum IgE levels measurement
Number of subjects: 10
Study: 8160978

Group type: EXPERIMENTAL
Intervention: Propofol alone
Number of subjects: 70

Group type: COMPARATOR
Intervention: Propofol plus nitrous oxide
Number of subjects: 70
Study: 3041826

Group type: EXPERIMENTAL
Intervention: Uniphyl tablets
Number of subjects: 12

Group type: COMPARATOR
Intervention: Theo-Dur tablets
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Uniphyl tablets and Theo-Dur tablets
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Theophylline phases
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo phase
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Uniphyl tablet phase
Number of subjects: 12
Study: 31861049

Group type: EXPERIMENTAL
Intervention: Nutraceutical composition containing creatine, D-ribose, vitamin B1, and vitamin B6
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 29903044

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 30
Study: 27013546

Group type: EXPERIMENTAL
Intervention: Entry to a $500 prize draw
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: $5 donation to charity
Number of subjects: 0

Group type: COMPARATOR
Intervention: No incentive (control)
Number of subjects: 0
Study: 23736378

Group type: EXPERIMENTAL
Intervention: FR-2 appliance treatment for 1.7 years
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (untreated class II subjects)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: FR-2 appliance treatment
Number of subjects: 34
Study: 22554048

Group type: EXPERIMENTAL
Intervention: Er:YAG laser debridement (ERL)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Manual scaling and root planning (SRP)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Comparison of ERL and SRP
Number of subjects: 19
Study: 19346292

Group type: EXPERIMENTAL
Intervention: Caspofungin
Number of subjects: 0
Study: 17244778

Group type: EXPERIMENTAL
Intervention: NXY-059
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 30
Study: 15082468

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg/day for 6 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg four times a day for 6 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient preference for Celecoxib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient preference for Acetaminophen
Number of subjects: 0
Study: 12149301

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus 5-FU (600 mg/m(2)/wk) weekly for 3 weeks of every 4 weeks
Number of subjects: 322

Group type: COMPARATOR
Intervention: Gemcitabine alone (1,000 mg/m(2)/wk) weekly for 3 weeks of every 4 weeks
Number of subjects: 322
Study: 10460103

Group type: EXPERIMENTAL
Intervention: Isoniazid (INH) 300 mg under fasting conditions
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Isoniazid (INH) 300 mg with aluminum-magnesium antacid
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Isoniazid (INH) 300 mg with a high-fat meal
Number of subjects: 14
Study: 8570532

Group type: EXPERIMENTAL
Intervention: Diltiazem sustained release pellets (coated with 0.6% ethylcellulose/dibutyl sebacate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cardizem tablets
Number of subjects: 0
Study: 2082314

Group type: EXPERIMENTAL
Intervention: Intramuscular ketorolac 30 mg
Number of subjects: 227

Group type: COMPARATOR
Intervention: Intramuscular morphine 10 mg
Number of subjects: 227
Study: 519877

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 7130407

Group type: EXPERIMENTAL
Intervention: Group condition (parent training plus group behavior therapy)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Individual condition (individual family behavior therapy)
Number of subjects: 15
Study: 30863856

Group type: EXPERIMENTAL
Intervention: Leukocyte apheresis (Group A)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Prednisolone (Group P)
Number of subjects: 24
Study: 28376460

Group type: EXPERIMENTAL
Intervention: Video intervention
Number of subjects: 62

Group type: COMPARATOR
Intervention: Print intervention
Number of subjects: 62
Study: 26044148

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone suppositories (400 mg daily starting at 20‐24 weeks of gestation)
Number of subjects: 250

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 250
Study: 24531792

Group type: EXPERIMENTAL
Intervention: 2% ketamine plus 4% amitriptyline (KA) cream
Number of subjects: 462

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 462
Study: 23050461

Group type: EXPERIMENTAL
Intervention: LaSota vaccine (virus titers ranging from 10(2) to 10(8) EID50 in 10-fold increments)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LaSota vaccine (adequate titer)
Number of subjects: 0
Study: 19572933

Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg pre-operatively (G2)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo pre-operatively (G1)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Placebo post-operatively (G3)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg post-operatively (G3)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo post-operatively (G1)
Number of subjects: 126
Study: 18097856

Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine
Number of subjects: 291

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Combined exacerbation rate during the first 14‐day interval
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Combined exacerbation rate during the second 14‐day interval
Number of subjects: 291
Study: 15089838

Group type: EXPERIMENTAL
Intervention: Veda-scope
Number of subjects: 250

Group type: COMPARATOR
Intervention: bivalve speculum
Number of subjects: 250
Study: 12059987

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 116
Study: 10094637

Group type: EXPERIMENTAL
Intervention: Lorazepam (2 mg in 2 ml of normal saline)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo (4 ml of normal saline)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 186
Study: 8789481

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 1981137

Group type: EXPERIMENTAL
Intervention: SK&F 86466 200 micrograms kg‐1
Number of subjects: 8
Study: 94637

Group type: EXPERIMENTAL
Intervention: Prazosin (5 mg q.i.d.)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Methyldopa (500 mg q.i.d.)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (50 mg twice daily)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Propranolol (substituted for prazosin or methyldopa)
Number of subjects: 16
Study: 31899371

Group type: EXPERIMENTAL
Intervention: Enhanced physical activity monitor (Fitbit wearable activity monitor and mobile app with goal setting and physical activity prescription)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Enhanced physical activity monitor + text messaging
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Personal calls
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Group meetings
Number of subjects: 312
Study: 28457189

Group type: EXPERIMENTAL
Intervention: Computerised cognitive remediation therapy (CCRT)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Active control
Number of subjects: 66
Study: 28753032

Group type: EXPERIMENTAL
Intervention: Aligner
Number of subjects: 41

Group type: COMPARATOR
Intervention: Traditional fixed appliance
Number of subjects: 41
Study: 25956341

Group type: EXPERIMENTAL
Intervention: Valnemulin hydrochloride premix at 20 ppm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valnemulin hydrochloride premix at 35 ppm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (non-medicated)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valnemulin hydrochloride (20 ppm and 35 ppm)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 0
Study: 23388155

Group type: COMPARATOR
Intervention: MD-GAL (0.9 g MD/kg body mass (BM) per h and 0.3 g GAL/kg BM per h)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: MD-GAL-PRO+AA (0.5 g MD/kg BM per h, 0.3 g GAL/kg BM per h, 0.4 g whey PRO hydrolysate plus l-leucine and l-phenylalanine/kg BM per h)
Number of subjects: 7
Study: 21846036

Group type: EXPERIMENTAL
Intervention: Vacuum-therapy
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control (no vacuum-therapy)
Number of subjects: 115
Study: 18772180

Group type: EXPERIMENTAL
Intervention: sirolimus-eluting stent (SES)
Number of subjects: 79

Group type: COMPARATOR
Intervention: paclitaxel-eluting stent (PES)
Number of subjects: 79
Study: 16465644

Group type: EXPERIMENTAL
Intervention: Methicillin-resistant Staphylococcus aureus (MRSA) colonization
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Methicillin-susceptible Staphylococcus aureus (MSSA) colonization
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Overall colonization
Number of subjects: 22
Study: 15248806

Group type: EXPERIMENTAL
Intervention: Adaptive directional microphone setting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fixed (cardioid) microphone setting
Number of subjects: 0
Study: 12131639

Group type: EXPERIMENTAL
Intervention: Histoacryl Blue (HAB)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Suturing
Number of subjects: 92
Study: 10454977

Group type: EXPERIMENTAL
Intervention: Tirofiban plus heparin and aspirin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Heparin and aspirin alone
Number of subjects: 100
Study: 7531732

Group type: EXPERIMENTAL
Intervention: Cetirizine (oral tablets) 10 mg twice daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2186802

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.75% irrigation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no bupivacaine irrigation)
Number of subjects: 0
Study: 399316

Group type: EXPERIMENTAL
Intervention: oestriol hemisuccinate (12 mg/day)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: oestriol hemisuccinate (4-6 mg/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 28
Study: 31286829

Group type: EXPERIMENTAL
Intervention: Pitch emphasis on the second word of the structure (modifier + N1 + N2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No pitch emphasis on the second word of the structure (modifier + N1 + N2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pitch emphasis with visual context available
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pitch prominence interpreted as syntax-encoding
Number of subjects: 0
Study: 29334176

Group type: EXPERIMENTAL
Intervention: LFCUD plus usual care (n = 33)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Usual care (n = 37)
Number of subjects: 70
Study: 27443664

Group type: EXPERIMENTAL
Intervention: 150 mg pregabalin capsule (generic product)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 150 mg pregabalin capsule (reference brand Lyrica)
Number of subjects: 0
Study: 25410607

Group type: EXPERIMENTAL
Intervention: Educational workshop plus access to internet-based support resources
Number of subjects: 220

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 220
Study: 23217470

Group type: EXPERIMENTAL
Intervention: Conventional gas‐torch brazing (G-TB)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Laser welding (LW)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Tungsten inert gas welding (TIG)
Number of subjects: 45
Study: 20549166

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation applied to knee extensor muscles for 4 weeks (30-60 minutes, 5 days/week)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Sham-stimulation
Number of subjects: 33
Study: 18722933

Group type: EXPERIMENTAL
Intervention: Colpopexy And Urinary Reduction Efforts (CARE) study
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Longitudinal Pelvic Symptoms and Patient Satisfaction After Colpocleisis cohort study
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Questionnaires completed by 23 physician investigators and 11 nurses or coordinators
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Colpocleisis study
Number of subjects: 34

Group type: COMPARATOR
Intervention: Older participants
Number of subjects: 34
Study: 15950141

Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation program over 1 year
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Body composition assessment using bioelectrical impedance (FFMI)
Number of subjects: 86
Study: 11821829

Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted distal gastrectomy (LADG)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Open distal gastrectomy (ODG)
Number of subjects: 28
Study: 10212949

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) at 750 mg/day or 1.5 g/day
Number of subjects: 394

Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 394
Study: 8702088

Group type: EXPERIMENTAL
Intervention: Acyclovir plus prednisone
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study: 1816110

Group type: EXPERIMENTAL
Intervention: Aciclovir (1,500 mg/m2/d)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Brivudin (15 mg/kg/d)
Number of subjects: 43
Study: 6809442

Group type: EXPERIMENTAL
Intervention: Propafenon
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mexiletine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tocainide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disopyramide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31982074

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (81 mg daily)
Number of subjects: 11976

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11976
Study: 30168613

Group type: EXPERIMENTAL
Intervention: Methylated DNA markers (MDMs) panel including HOXA1, EMX1, AK055957, ECE1, PFKP, CLEC11A normalized by B3GALT6 level
Number of subjects: 295

Group type: COMPARATOR
Intervention: Alpha-fetoprotein (AFP)
Number of subjects: 295
Study: 29849178

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (0.33 to 4.50 g EPA+DHA/day) for 14 days
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Flaxseed oil supplementation (5.90-6.60 g/d) for 14 days
Number of subjects: 303
Study: 26227655

Group type: EXPERIMENTAL
Intervention: Participants (n=266)
Number of subjects: 560

Group type: COMPARATOR
Intervention: Non-participants (n=292)
Number of subjects: 560
Study: 24594468

Group type: EXPERIMENTAL
Intervention: Artificial simulator training
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Live animal training
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both training modalities
Number of subjects: 27
Study: 22040016

Group type: EXPERIMENTAL
Intervention: Parent‐Child Interaction Therapy Emotion Development (PCIT‐ED)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Psycho-education
Number of subjects: 54
Study: 20582464

Group type: EXPERIMENTAL
Intervention: Anthracycline response (FEC and AC)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Taxane resistance (TET chemotherapy)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: AC responders (from FFPE samples)
Number of subjects: 105
Study: 18048574

Group type: EXPERIMENTAL
Intervention: Amlodipine (placebo, 5, or 10 mg) and Atorvastatin (placebo, 10, 20, 40, or 80 mg)
Number of subjects: 1660

Group type: EXPERIMENTAL
Intervention: Combination treatment of atorvastatin and amlodipine
Number of subjects: 1660
Study: 16221232

Group type: EXPERIMENTAL
Intervention: HB‐AS04 vaccine (Fendrix, GlaxoSmithKline Biologicals)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Standard vaccine (Engerix, GlaxoSmithKline Biologicals)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 119
Study: 12361241

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 16
Study: 9987467

Group type: EXPERIMENTAL
Intervention: Home-based resistance exercise training
Number of subjects: 215

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 215
Study: 7757309

Group type: EXPERIMENTAL
Intervention: 30 mg nimodipine t.i.d. for 7 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: nifedipine
Number of subjects: 12

Group type: COMPARATOR
Intervention: nimodipine
Number of subjects: 12

Group type: COMPARATOR
Intervention: nimodipine and nifedipine
Number of subjects: 12
Study: 1554276

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Packed red blood cells (PC)
Number of subjects: 40
Study: 3998617

Group type: EXPERIMENTAL
Intervention: [1‐13C]stearic acid
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: [1‐13C]oleic acid
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: [1‐13C]linoleic acid
Number of subjects: 6
Study: 31987248

Group type: EXPERIMENTAL
Intervention: Korean red ginseng (KRG) 3 g for 6 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 29556335

Group type: EXPERIMENTAL
Intervention: High sodium diet (150 mmol sodium intake per day)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Low sodium diet (50 mmol sodium intake per day)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Treatment with β‐aminoisobutyric acid in Dahl salt-sensitive rats
Number of subjects: 103
Study: 25731657

Group type: EXPERIMENTAL
Intervention: Carbetocin (100 μg IM)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Oxytocin (5 IU IM)
Number of subjects: 200
Study: 25257612

Group type: EXPERIMENTAL
Intervention: Supervised progressive resistance training (PRT) for 24 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-guided physical activity after 24 weeks of supervised PRT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist group undergoing supervised PRT after 24 weeks of habitual lifestyle
Number of subjects: 0
Study: 23418994

Group type: EXPERIMENTAL
Intervention: TABADO program (community-based smoking cessation program) including general information session, small-group sessions, individual counselling, and nicotine therapy if needed.
Number of subjects: 1814

Group type: COMPARATOR
Intervention: Control group (no specific intervention, only usual educational services).
Number of subjects: 1814
Study: 21219392

Group type: EXPERIMENTAL
Intervention: Er:YAG laser (ERL)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Plastic curets + cotton pellets + sterile saline (CPS)
Number of subjects: 32
Study: 17634853

Group type: EXPERIMENTAL
Intervention: Monarc sling (n = 80)
Number of subjects: 187

Group type: COMPARATOR
Intervention: TVT (n = 107)
Number of subjects: 187
Study: 16476840

Group type: EXPERIMENTAL
Intervention: Epoetin alfa at a dose of 10,000 U thrice weekly s.c.
Number of subjects: 316

Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 316
Study: 12924540

Group type: EXPERIMENTAL
Intervention: IL-2 combined with HAART
Number of subjects: 70

Group type: COMPARATOR
Intervention: HAART alone
Number of subjects: 70

Group type: COMPARATOR
Intervention: IL-2 (after 6 months)
Number of subjects: 70
Study: 10607690

Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA) during induction and maintenance therapy
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Chemotherapy without further ATRA
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: No ATRA and no chemotherapy
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Maintenance therapy with ATRA
Number of subjects: 44
Study: 9624473

Group type: EXPERIMENTAL
Intervention: Trimethoprim (TMP) 10 mg/kg/day and Sulfamethoxazole (SMX) 50 mg/kg/day
Number of subjects: 77

Group type: COMPARATOR
Intervention: Pyrimethamine (P) 50 mg/day and Sulfadiazine (S) 60 mg/kg/day
Number of subjects: 77